نتایج جستجو برای: hiv 1 dna vaccine

تعداد نتایج: 3346593  

2015
Vinicius Canato Santana Rafael Ribeiro Almeida Susan Pereira Ribeiro Luís Carlos de Souza Ferreira Jorge Kalil Daniela Santoro Rosa Edecio Cunha-Neto

T-cell based vaccines against human immunodeficiency virus (HIV) generate specific responses that may limit both transmission and disease progression by controlling viral load. Broad, polyfunctional, and cytotoxic CD4+T-cell responses have been associated with control of simian immunodeficiency virus/HIV-1 replication, supporting the inclusion of CD4+ T-cell epitopes in vaccine formulations. Pl...

Journal: :Molecular therapy : the journal of the American Society of Gene Therapy 2004
Robert M Frederickson

nificantly improved performance in motor skills tests relative to control-treated SCA1 mice. These data provide the first in vivo demonstration of efficacy of RNAi for dominant neurodegenerative disease therapy. The third abstract was authored by Hildegund Ertl, who described her group’s efforts to test a new vaccine platform based on E1-deleted adenoviral vectors derived from chimpanzee seroty...

Journal: :Journal of virology 2007
Robert De Rose C Jane Batten Miranda Z Smith Caroline S Fernandez Viv Peut Scott Thomson Ian A Ramshaw Barbara E H Coupar David B Boyle Vanessa Venturi Miles P Davenport Stephen J Kent

Vaccination against AIDS is hampered by great diversity between human immunodeficiency virus (HIV) strains. Heterologous B-subtype-based simian-human immunodeficiency virus (SHIV) DNA prime and poxvirus boost vaccine regimens can induce partial, T-cell-mediated, protective immunity in macaques. We analyzed a set of DNA, recombinant fowlpox viruses (FPV), and vaccinia viruses (VV) expressing sub...

2017
Nathifa Moyo Nicola J Borthwick Edmund G Wee Silvia Capucci Alison Crook Lucy Dorrell Tomáš Hanke

BACKGROUND Durability of vaccine-elicited immune responses is one of the key determinants for vaccine success. Our aim is to develop a vaccination strategy against the human immunodeficiency virus type 1 (HIV-1), which induces protective and durable CD8+ T-cell responses. The central theorem of our approach is to focus T cells on highly conserved regions of the HIV-1 proteome and this is achiev...

2011
Sean X. Du Li Xu Wenge Zhang Susan Tang Rebecca I. Boenig Helen Chen Ellaine B. Mariano Michael B. Zwick Paul W. H. I. Parren Dennis R. Burton Terri Wrin Christos J. Petropoulos John A. Ballantyne Michael Chambers Robert G. Whalen

A prophylactic vaccine is needed to slow the spread of HIV-1 infection. Optimization of the wild-type envelope glycoproteins to create immunogens that can elicit effective neutralizing antibodies is a high priority. Starting with ten genes encoding subtype B HIV-1 gp120 envelope glycoproteins and using in vitro homologous DNA recombination, we created chimeric gp120 variants that were screened ...

2012
Spyros A. Kalams Scott Parker Xia Jin Marnie Elizaga Barbara Metch Maggie Wang John Hural Michael Lubeck John Eldridge Massimo Cardinali William A. Blattner Magda Sobieszczyk Vinai Suriyanon Artur Kalichman David B. Weiner Lindsey R. Baden

BACKGROUND DNA vaccines are a promising approach to vaccination since they circumvent the problem of vector-induced immunity. DNA plasmid cytokine adjuvants have been shown to augment immune responses in small animals and in macaques. METHODOLOGY/PRINCIPAL FINDINGS We performed two first in human HIV vaccine trials in the US, Brazil and Thailand of an RNA-optimized truncated HIV-1 gag gene (p...

2013
Marie Borggren Lasse Vinner Betina Skovgaard Andresen Berit Grevstad Johanna Repits Mark Melchers Tara Laura Elvang Rogier W Sanders Frédéric Martinon Nathalie Dereuddre-Bosquet Emma Joanne Bowles Guillaume Stewart-Jones Priscilla Biswas Gabriella Scarlatti Marianne Jansson Leo Heyndrickx Roger Le Grand Anders Fomsgaard

HIV-1 DNA vaccines have many advantageous features. Evaluation of HIV-1 vaccine candidates often starts in small animal models before macaque and human trials. Here, we selected and optimized DNA vaccine candidates through systematic testing in rabbits for the induction of broadly neutralizing antibodies (bNAb). We compared three different animal models: guinea pigs, rabbits and cynomolgus maca...

Journal: :Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology 2011
Eva Van Braeckel Marguerite Koutsoukos Patricia Bourguignon Frédéric Clement Lisa McNally Geert Leroux-Roels

BACKGROUND Vaccine-induced antibodies to envelope proteins frequently cause HIV seroconversion in uninfected recipients of HIV vaccine candidates and may thus have an impact on the vaccinee's ability to donate blood or acquire a life insurance policy. OBJECTIVE To determine the occurrence of positive test results when commonly used HIV immunoassays are used to screen sera of HIV-uninfected vo...

2010
Susan Pereira Ribeiro Daniela Santoro Rosa Simone Gonçalves Fonseca Eliane Conti Mairena Edilberto Postól Sergio Costa Oliveira Luiza Guilherme Jorge Kalil Edecio Cunha-Neto

Current HIV vaccine approaches are focused on immunogens encoding whole HIV antigenic proteins that mainly elicit cytotoxic CD8+ responses. Mounting evidence points toward a critical role for CD4+ T cells in the control of immunodeficiency virus replication, probably due to cognate help. Vaccine-induced CD4+ T cell responses might, therefore, have a protective effect in HIV replication. In addi...

پایان نامه :وزارت علوم، تحقیقات و فناوری - دانشگاه تربیت مدرس 1388

تا کنون 60 میلیون نفر با hiv آلوده شده اند که نزدیک به 22 میلیون نفر از آنها جان خود را از دست داده اند. هزینه درمانی هر فرد مبتلا به ایدز سالانه در حدود 20000 دلار می باشد. داروهای ضد رتروویروسی کنونی به طور کامل نمی توانند افراد آلوده به ویروس را پاکسازی نمایند و نیز با مصرف دارو، واریانتهای مقاوم به دارو تولید می گردد. این مسائل نشان می دهد، استفاده از یک واکسن پیشگیری کننده ایمن و موثر شدید...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید